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Abstract
Studies from the Far East have demonstrated that 
D2-dissection is superior to D0/1-dissection. The ef-
fect of postoperative chemoradiotherapy (CRT) after 
D2-dissection has not been accepted due to the lack 
of D2-dissection in Western countries, as well as the 
potential harmful effect of radiotherapy. In the current 
NCCN guideline, adjuvant chemotherapy alone is rec-
ommended in D2-dissected patients. However, three 
recent prospective randomized controlled trials in South 
Korea and China (ARTIST, NCC and Multicenter IMRT 
Trials) demonstrated that adjuvant CRT can be safely 
administered to D2-dissected patients with notable 
benefits. To identify the role of radiotherapy (RT) in the 
D2-dissected postoperative setting, clinical research 
attempts should include (1) identification of high-risk 
patients for loco-regional recurrence who might benefit 
from CRT; (2) modification of RT target volume based 
on the findings that failure patterns should be differ-
ent after D1- and D2-dissection; and (3) integration 
of new RT techniques to decrease treatment-related 
toxicity. The present paper is a review of recent studies 
addressing these fields. Well-designed prospective ran-
domized studies are needed to clearly define the role of 
adjuvant CRT in D2-dissected gastric cancer, however, 
future clinical studies should also focus on answering 
these questions. 
© 2014 Baishideng Publishing Group Inc. All rights reserved.
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Core tip: The survival benefits of postoperative chemo-
radiotherapy (CRT) in gastric cancer with D0/1-
dissection have been established in Western countries. 
However, in Eastern areas, where D2-dissection is the 
standard surgical procedure, most surgeons are skepti-
cal about the benefit of CRT in D2-dissected patients, 
and CRT has not been examined in this setting in clini-
cal trials. Here we aimed to provide a review of recent 
research and to suggest future directions regarding 
adjuvant CRT after D2-dissection. 
Chang JS, Koom WS, Lee Y, Yoon HI, Lee HS. Postoperative 
adjuvant chemoradiotherapy in D2-dissected gastric cancer: Is ra-
diotherapy necessary after D2-dissection? World J Gastroenterol 
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INTRODUCTION 
During the past two decades, a multimodal treatment 
combining chemotherapy and chemoradiotherapy (CRT) 
has been investigated worldwide to prevent recurrence 
and improve survival in gastric cancer patients who un-
derwent curative surgical resection[1]. Due to the lack of  
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robust evidence as to which of  the currently available 
approaches is better, there has been marked discrepancy 
in adjuvant treatment nationwide and worldwide. In the 
West, peri-operative intensive chemotherapy (MAGIC 
trial) and postoperative CRT (SWOG/INT-0116 trial) 
are recommended for resectable gastric cancer[2,3]. In 
the East, on the other hand, adjuvant chemotherapy af-
ter D2-dissection is considered the standard treatment 
(ACTS-GC and CLASSIC trials). Studies from the Far 
East have demonstrated that D2-dissection is superior 
to D0/1-dissection. The effect of  postoperative CRT 
after D2-dissection has not been accepted due to the 
lack of  D2-dissection in Western countries, as well as the 
potential harmful effect of  radiotherapy[4,5]. However, 
three recent prospective randomized controlled trials in 
South Korea and China have demonstrated that adjuvant 
CRT can be safely administered to D2-dissected patients 
with notable benefits[6-8]. Currently, some important clini-
cal questions still remain unanswered: (1) Does adjuvant 
CRT in D2-dissected patients provide similar benefit to 
that shown in the SWOG/INT-0116 trial (mostly D0/1-
dissected patients)? (2) What is the incidence of  loco-
regional recurrences, which sometimes mimic metastatic 
peritoneal seeding or distant lymph nodes, after D2-dis-
section? (3) If  CRT is considered as adjuvant treatment 
for D2-dissection fields, is it necessary to modify the tra-
ditional radiation field, which was developed for D0/1-
dissected fields? (4) Is radiation therapy still potentially 
harmful even with modern radiotherapy (RT) techniques 
and modified RT fields in gastric cancer? and (5) Is there 
a subset of  patients with specific characteristics who 
would benefit from adjuvant CRT after D2-dissection? 
This review discusses the current status of  adjuvant CRT 
for gastric cancer patients undergoing D2-dissection, 
with updated data to provide a guide to the priorities on 
which investigators should focus on in future studies.
RATIONALE FOR ADJUVANT 
RADIOTHERAPY IN GASTRIC CANCER
High rates of  local and regional recurrence have been 
shown in patients with gastric cancer treated with surgical 
resection. The reported rate of  loco-regional recurrence 
ranges from 19%-45%, and reported loco-regional recur-
rence from re-operation or autopsy data is up to 90%[9-13]. 
Gunderson et al[14] suggested potential radiation portals 
based on the patterns of  loco-regional failures in the re-
operation group, leading investigators to verify the role 
of  radiotherapy in preventing such recurrence[14-17]. 
The SWOG/INT-0116 trial, directly compared 
postoperative CRT with observation alone, and clearly 
showed the survival benefit of  postoperative CRT in re-
sected gastric cancer[3]. Even though the eligibility criteria 
included stage ⅠB through IVM0 (AJCC 1988), most 
of  the enrolled patients were at high risk for recurrence 
(T3/4, 69% and N+, 85%). CRT consisted of  45 Gy of  
radiation with concurrent bolus 5-fluorouracil/leucovorin 
(FL) (Figure 1). RT-related gastrointestinal toxicity may 
have been severe, in that only 64% of  patients completed 
the planned treatment. Nonetheless, three-year relapse-
free survival and overall survival (OS) were significantly 
improved by adjuvant CRT in a median follow-up of  
five years, which led to its adoption as standard treat-
ment in the United States. Since the publication of  the 
SWOG/INT-0116 trial results, adjuvant CRT was found 
to be used more commonly in United States based on 
the SEER database analysis (33% in 1998-2001 vs 45% in 
2002-2007, P < 0.001)[18]. The updated data after 10-y of  
follow up in SWOG/INT-0116, demonstrated a persis-
tent benefit of  adjuvant CRT[19]. The rate of  loco-regional 
failure, but not distant relapse, was significantly decreased 
in the group treated with adjuvant CRT, suggesting that 
the improved OS by adjuvant CRT was mainly due to 
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Figure 1  Treatment and randomization schemes of the SWOG/INT-0116 and ARTIST trials. 5-FU: 5-fluorouracil.
the prevention of  subclinical loco-regional diseases. The 
long-term toxicity, including secondary malignancies, ap-
peared acceptable.
EXTENT OF LYMPH NODE DISSECTION 
Could these findings lead to the adoption of  adjuvant 
CRT for gastric cancer patients in Eastern countries? As 
only a minority of  patients [54 (10%) of  552] in SWOG/
INT-0116 underwent D2-dissection, an extremely con-
servative approach has been followed in Eastern areas, 
such as South Korea and Japan where D2-dissection has 
long been the standard[20]. Over the past few decades, 
whether the extent of  lymph node dissection (D1 vs D2) 
favorably impacts survival outcome has been a controver-
sial issue. Two prospective randomized controlled trials 
in the West addressed this controversial issue: thereafter, 
it took a long time to provide robust evidence that D2-
dissection improves survival over D1-dissection when 
performed by well-trained surgeons with acceptable rates 
of  postoperative mortality[21,22]. 
MRC trial 
The Medical Research Council (MRC) in the United 
Kingdom randomized 400 patients to D1 resection or 
D2 resection[21]. The rates of  postoperative morbidity and 
mortality were significantly higher in the D2 group (46% 
vs 28% and 13% vs 7%, respectively), which was due to 
splenectomy and distal pancreaticosplenectomy. In an up-
date with a median follow-up time of  6.5 years, five-year 
survival rate following D2-dissection was not better than 
that following D1-dissection (33% vs 35%)[23]. 
Dutch trial 
Another large prospective randomized controlled trial was 
conducted by the Dutch Gastric Cancer Group (DCGC) 
in the Netherlands, which randomized 711 patients to 
D1 or D2 dissection[22]. The Dutch trial by Bonenkamp et 
al[22] had a unique characteristic regarding quality control 
of  surgical management compared to the MRC trial in 
that the participating surgeons were instructed by Japa-
nese surgeons during the first four months. The results 
were similar to those in the MRC trial in that postopera-
tive morbidity and mortality rates were higher; however 
five-year survival rate was not higher in the D2 group. 
The incidence of  postoperative complications and death 
were 43% and 10% in the D2 group, and 25% and 4% in 
the D1 group. Even though an updated report with more 
than 10 years follow-up found that D2-dissection did 
not generate long-term survival benefits, the latest report 
after a follow-up of  15 years showed lower loco-regional 
recurrence and gastric cancer-related death in the D2-
group[24,25]. Collectively, regardless of  whether the patients 
were treated in the East or not, D2-dissection is now 
recommended for resectable gastric cancer patients if  it 
is performed by well-trained surgeons in high-volume 
centers. 
ADJUVANT CRT IN D2-DISSECTED 
GASTRIC CANCER
Only a few small prospective studies and several retro-
spective studies have explored the role of  adjuvant CRT 
in D2-dissected gastric cancer[26-30]. Dikken et al[26], using 
a Dutch cohort, compared 91 patients who received ad-
juvant CRT in two phase Ⅰ/Ⅱ studies with 694 patients 
from the DCGC D1/D2 trial. In this study, the addi-
tion of  CRT seemed to be beneficial in preventing local 
recurrence after D1-dissection, but not after D2-dissec-
tion. However, in the updated analysis of  the SWOG/
INT-0116 study with a 10-year follow-up, there was no 
evidence of  lack of  survival benefit in patients who had 
undergone the D2 level of  resection. A retrospective 
study by Kim et al[27] in South Korea showed improved 
survival and lower regional recurrence by adding CRT, 
albeit in patients who underwent D2-dissection. The 
five-year survival rates were consistently longer in the 
adjuvant CRT group (n = 554) at stages Ⅱ, Ⅲ, and Ⅳ 
compared with those in the comparison group (n = 446). 
However, these data are based on unplanned subgroup 
analysis or nonrandomized observation studies with suit-
able controls (level Ⅲ).
RECENT TRIALS OF ADJUVANT CRT 
AFTER D2-DISSECTION
There has been no evidence directly comparing adjuvant 
chemotherapy, which is a standard treatment in Eastern 
countries for D2-dissected gastric cancer[28]. In 2012, the 
findings of  three prospective randomized controlled trials 
were published, however, the results were inconclusive[6-8]. 
ARTIST trial, South Korea 
The Adjuvant Chemoradiation Therapy in Stomach Can-
cer (ARTIST) trial, led by the same authors as the afore-
mentioned observational study by Kim et al[7], was the first 
and largest prospective study to address the role of  CRT 
as adjuvant treatment in D2-dissected gastric cancer[6]. 
This study randomly assigned 458 patients undergoing 
complete resection with D2-dissection to six cycles of  ad-
juvant capecitabine with cisplatin (XP, n = 228) or 45 Gy 
of  CRT with concurrent capecitabine following two cycles 
of  XP and two additional cycles of  XP (n = 230) (Figure 
1). Over a median follow-up of  53 mo, no statistically 
significant difference in three-year disease-free survival 
(DFS) between the two groups (XP: 74% vs CRT: 78%, 
P = 0.0862) was found. However, this trial should not be 
interpreted as a negative result for adjuvant CRT in D2-
dissection. Since the implementation of  the nationwide 
cancer screening program in South Korea (GI endoscopic 
examination in individuals aged over 40 years every two 
years), a significant proportion of  enrolled patients were 
stage I/Ⅱ disease; therefore, the planned events were 
not reached at the time of  final analysis. The unplanned 
subset analysis revealed that the combined modality sig-
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motherapy consisted of  the FL regimen in both groups. 
With a median follow-up of  43 mo, adjuvant CRT was 
associated with a significant reduction in the risk of  recur-
rence (5-year DFS, 45% vs 36%), and with no significant 
survival advantage (5-year OS, 48% vs 42%). Not surpris-
ingly, no difference in the rate of  distant metastasis was 
noted between the two groups (24% vs 27%, P = 0.595), 
and loco-regional recurrences were less frequent in the 
adjuvant CRT group (15% vs 24%, P = 0.042). 
DISCUSSION OF RECENT TRIALS 
The results of  three recent randomized controlled tri-
als from South Korea and China comparing adjuvant 
chemotherapy and CRT, which included a total of  
895 patients in the meta-analysis, showed no apparent 
survival benefit with the addition of  RT (HR = 0.79, 
95%CI: 0.61-1.03) during the 4-7 year follow-up pe-
riod, but found significantly improved LRRFS (HR = 
0.53, 95%CI: 0.32-0.87) and DFS (HR = 0.72, 95%CI: 
0.59-0.89) in the CRT group (Table 1)[31]. When interpret-
ing the findings of  these trials, several important points 
should be considered. Firstly, although in the SWOG/
INT-0116 trial, 41% of  CRT patients experienced severe 
treatment-related toxicity, resulting in only 64% com-
nificantly improved the three-year DFS in node positive 
patients, supporting the hypothesis of  this trial. 
NCC trial, South Korea 
The National Cancer Center (NCC) in South Korea con-
ducted a single-institution phase Ⅲ trial in stage Ⅲ-Ⅳ 
gastric cancer patients who underwent R0 gastrectomy 
and D2-dissection[7]. A total of  90 patients were random-
ly assigned to the chemotherapy arm (FL, n = 44) or the 
CRT arm (INT-0116 scheme, n = 46). Unfortunately, this 
underpowered study was terminated early due to poor 
accrual (possibly why the ARTIST trial included 60% 
stage Ⅰ/Ⅱ patients). Although five-year DFS, which was 
the primary endpoint of  this trial, was not significantly 
improved in the combined modality group which includ-
ed RT, the five-year loco-regional recurrence-free survival 
(LRRFS, secondary endpoint) was significantly improved 
in the median follow-up of  87 mo.  
Multicenter IMRT trial, China 
In contrast to these two trials, a significant benefit in DFS, 
but not in OS, was shown in a Chinese multicenter ran-
domized trial, in which patients with D2-dissection were 
randomly assigned to chemotherapy alone or intensity-
modulated RT plus concurrent chemotherapy[8]. The che-
Table 1  Major patient characteristics and results of phase Ⅲ trials of postoperative radiotherapy for gastric cancer
Ref. n Enrolled 
period
Median F/u (m) pT3-4 pN+ Ⅲ-Ⅳ D2 OS DFS/RFS Remarks
SWOG/INT-0116[3] 556 91-98 60 70% 85% NR   10% 3-yr: 50% vs 41%
(P = 0.005)
3-yr: 48% vs 31%
(P < 0.001)
Similar benefit in 
10-yr follow-up 
data
ARTIST[6] 458 04-08 53 NR 86%   41% 100% NR 3-yr: 78% vs 74%
(P = 0.0862)
DFS benefit in N+
NCC, South Korea[7]   90 02-06 87 63% 98% 100% 100% 5-yr: 65% vs 55%
(P > 0.05)
5-yr: 61% vs 50%
(P > 0.05)
LRRFS benefit
(DFS benefit in 
stage Ⅲ)
IMRT, China[8] 351 03-08 43 NR 86%   71% Majority 5-yr: 48% vs 42%
(P = 0.122)
5-yr: 45% vs 36%
(P = 0.029)
F/u: Follow-up; PS: Performance status; NR: Not reported; OS: Overall survival; DFS/RFS: Disease-free survival/relapse-free survival; LRRFS: Loco-
regional failure-free survival. 
Table 2  Treatment parameters and toxicities in phase III studies of postoperative radiotherapy for gastric cancer
Ref. Group Concurrent 
chemo
RT planning RT dose 
(Gy)
RT target Severe toxicity Completed planned 
treatment
SWOG/INT-0116[3] CRT 5FU + LV 2D 45 Tumor bed, LN 
(Nos. 1-16)
G3+, 41%, G4+ 32%
(GI, 33%)
64%
(17 due to toxic effect)
ARTIST[6] CT-CRT-CT Capecitabine 2D or 3D 45 LN (Nos. 7-9 and 
12-16)
Similar toxicity profile 
between the two groups 
(mostly well tolerated)
82% (5 due to toxic 
effect, but 1 during CRT)
NCC, South Korea[7] CRT 5FU + LV 2D or 3D 45 Tumor bed, LN 
(Nos. 1-16)
G3+ Hema; 20% vs 25%, G3+ 
GI; 17% vs 11%
87% (2 due to toxic 
effect)
IMRT, China[8] CRT 5FU + LV IMRT 45 Tumor bed, LN 
(Nos. 1-16)
Similar toxicity profile 
between the two groups 
(mostly well tolerated)
91% (4 due to toxic 
effect)
RT: Radiotherapy; CRT: Chemo-radiotherapy; 5FU + LV: Fluorouracil and leucovorin; LN: Lymph node; GI: Gastrointestinal; Hema: Hematologic; IMRT: 
Intensity modulated radiotherapy. 
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pleted planned treatments, in 3 recent randomized trials, 
no increase in treatment-related toxicity was observed in 
the CRT group compared with the chemotherapy alone 
group; consequently, most patients (ARTIST 75%, NCC 
87%, and China 91%) completed treatment as planned 
(Table 2). One plausible explanation for this is the ap-
plication of  modern RT techniques (IMRT or CT-based 
3D-CRT) in recent trials rather than 2D-conventional 
RT in the SWOG/INT-0116 trial carried out in the 1990’
s and/or the modification of  RT target volume in the 
ARTIST trial, which could reduce the irradiating bowel 
volume. Secondly, the patient population varied between 
the studies. The proportion of  stage Ⅲ/Ⅳ disease, which 
could involve a high risk of  loco-regional relapse, was 
41% in the ARTIST trial, 71% in the Chinese trial, and 
100% in the NCC trial. The positive results for DFS in 
the Chinese trial and subset (N+) analysis of  the ARTIST 
trial indicated that the use of  adjuvant CRT for the entire 
population undergoing D2-dissection may be overtreat-
ment, and, therefore, identification of  the high-risk sub-
group which would benefit most from CRT should be 
carried out. 
LOCOREGIONAL RECURRENCE AFTER 
D2-DISSECTION: IMPLICATIONS FOR 
POSTOPERATIVE RT
In Eastern countries including South Korea and Japan, 
D2-dissection with low morbidity and mortality is be-
lieved to contribute to rare loco-regional recurrence and 
a high OS rate[32]. However, actual reported rates of  lo-
cal/regional recurrence after D2-dissection range from 
19%-33%[12,25,27]. The largest retrospective study from 
South Korea analyzed the failure patterns of  2328 pa-
tients who underwent D2-dissection, and reported 19% 
of  loco-regional recurrence as a single pattern and 33% 
as a combined pattern[12]. Another retrospective study 
from Korea reported 22% of  loco-regional failure in 446 
patients who did not receive adjuvant RT[27]. In the Dutch 
D1/D2 trial from DCGC, a similar rate of  loco-regional 
recurrence was noted in 331 patients in the D2 group 
(local 12% and regional 13%)[25]. It should be noted that 
these studies included entire patient populations from 
stage Ⅰ to stage Ⅳ (M0) disease. One possible explana-
tion for under-reporting of  loco-regional recurrence 
included lack of  attention due to distant spread and dif-
ficulty in determining loco-regional failure using current 
imaging modalities. The intra-abdominal location of  
regional lymph nodes (LNs) could make recurrence less 
likely to be detected as the first failure pattern compared 
with other organs. 
In the present authors’ opinion, the identification of  
a high-risk subgroup for loco-regional recurrence among 
D2-dissected patients is essential and of  higher priority 
than assessing the efficacy of  regular application of  adju-
vant CRT in all D2-dissected gastric cancer patients. The 
subgroup analysis in the ACTS-GC trial from Japan may 
provide a clue to identifying patients who are most likely 
to benefit from adjuvant CRT[33]. The pivotal Japanese 
ACTS-GC study demonstrated the survival advantage 
of  postoperative S-1 chemotherapy over observation[4]. 
Subgroup analysis of  5-year OS in this study showed that 
insufficient survival benefit of  S-1 was observed in N3a 
(HR = 0.779, 95%CI: 0.534-1.138) and N3b stages (HR 
= 0.927, 95%CI: 0.477-1.799), in contrast to clear efficacy 
in N0-N2 stages, which may indicate room for improve-
ment in the application of  RT in these patients at high 
risk for loco-regional recurrence. In Korea, the report 
by Chang et al[34] revealed an interesting finding that N3 
patients are at substantial risk of  regional recurrence as 
well as peritoneal seeding and distant spread despite D2 
dissection and adjuvant chemotherapy. The report also 
demonstrated that the most frequent locations of  region-
al recurrence were in the nodal stations outside the D2-
dissection field (12p-16), which are classified as distant 
metastasis (M1 node) according to the 7th edition of  the 
AJCC classification system, but as regional node accord-
ing to the Japanese Classification of  Gastric Carcinoma 
(JCGC) criteria (Table 3)[35]. 
RT TARGET VOLUME COULD BE 
MODIFIED IN D2-DISSECTED GASTRIC 
CANCER 
The RT target volume has varied in the studies of  adju-
vant RT[36]. In the SWOG/INT-0116 trial, the field of  
radiation included the tumor bed and 2 cm beyond the 
proximal and distal margins of  resection, and regional 
nodes (perigastric, celiac, local para-aortic, splenic, hepa-
Table 3  Description of lymph node station
LN station Node location
1 LN at right paracardium
2 LN at left paracardium
3 LN along the lesser curvature
4 LN along the greater curvature
5 LN at suprapylorum
6 LN at infrapylorum
7 LN along the left gastric artery
8 LN along the common hepatic artery
9 LN around the celiac artery
10 LN at the splenic hilum
11 LN along the proximal splenic artery
12 LN in the hepatoduodenal ligament
12a LN along the hepatic artery
12b LN along the bile duct
12p LN behind the portal vein
13 LN on the posterior surface of the pancreatic head
14 LN along the superior mesenteric vessels
15 LN along the middle colic vessels
16 LN around the abdominal aorta
16a LN from the upper margin of the celiac trunk to the lower 
margin of the left renal vein
16b LN from the upper margin of the left renal vein to the 
aortic bifurcation
Chang JS et al . Radiation therapy in D2-dissected gastric cancer
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toduodenal, and pancreaticoduodenal LNs)[3,14]. This 
field was defined based on patterns of  failure after D0/1 
dissection in a Western population, which might be the 
representative failure pattern of  suboptimal surgical re-
section. On the other hand, in the ARTIST trial, the RT 
target volume did not include LNs in the splenic hilum 
(No. 10), LNs along the proximal splenic artery (No. 11), 
perigastric LNs (Nos. 1-6) and tumor bed, based on their 
previous study analyzing patterns of  failure after D2-
dissection (Figure 2)[6,37]. 
Coupled with a retrospective central review by one 
GI radiologist, Chang et al[34] investigated patterns of  LN 
recurrence after D2 dissection for 382 patients with stage 
Ⅲ (N3) disease. The most prevalent regional recurrence 
was LNs around the abdominal aorta from the upper 
margin of  the celiac trunk to the lower margin of  the 
aortic bifurcation (Nos. 16a and 16b), followed by hepa-
toduodenal LNs (No. 12), LNs along superior mesenteric 
vessels (No. 14), retropancreatic LNs (No. 13), and celiac 
LNs (No. 9). These results provide consistent evidence 
that RT target volume in D2-dissected patients can ex-
clude perigastric LNs (Nos. 1-6), and splenic LNs (Nos. 
10-11). Since the development of  severe gastrointestinal 
complications is mostly attributed to the extent of  the 
RT target volume in gastric cancer, understanding the 
specific location of  loco-regional recurrence after D2-
dissection could potentially allow more effective RT strat-
egies. A subsequent report by Yoon et al[38] demonstrated 
RT target volume delineation based on CT-guided vascu-
lar structure using the data from 91 patients who had LN 
recurrence from their previous study. 
CURRENT TRIALS 
Well-designed prospective randomized studies with ad-
equate statistical power are needed to clearly define the 
role of  adjuvant CRT in D2-dissected gastric cancer. 
The ChemoRadiotherapy after Induction chemoTherapy 
In Cancer of  the Stomach (CRITICS) trial is currently 
randomizing patients undergoing preoperative ECF 
followed by D1+ dissection (Nos. 1-9 and 11) to post-
operative ECF alone or 45 Gy of  CRT with concurrent 
capecitabine plus cisplatin, and comparing the efficacy of  
the MAGIC trial regimen which showed the survival ben-
efit of  a perioperative approach combined with intensive 
chemotherapy (ECF; epirubicin, capecitabine, and cis-
platin) with those of  the SWOG/INT-0116 trial[39]. The 
ARTIST Ⅱ trial plans to accrue LN positive patients us-
ing a 2-by-2 factorial design of  chemotherapy agents (S-1 
vs capecitabine plus oxaliplatin) and treatment modality 
(chemotherapy alone vs CRT). 
CONCLUSION
Current treatment guidelines of  adjuvant CRT for D2-
dissected gastric cancer are based on low-level evidence 
due to a paucity of  prospective studies and a near total 
absence of  phase Ⅲ multicenter randomized trials. Re-
cent prospective randomized trials from South Korea 
and China demonstrated that the addition of  RT to 
chemotherapy could prevent loco-regional recurrence 
and, furthermore, improve DFS in selected patients even 
after D2-dissection. Considerable rates of  loco-regional 
recurrence have been reported after D2-dissection and 
the most prevalent locations of  recurrence are found in 
the nodal basin outside the D2-dissection field. Whether 
modification of  RT target volume and/or new RT tech-
niques can reduce GI toxicity without compromising 
the oncologic outcomes is a clinically relevant question. 
Identification of  high-risk patients for loco-regional 
recurrence is crucial. Because D2-dissection has been 
recently recommended as the standard surgical method 
worldwide, data on the influence of  clinical results is now 
available from both Eastern and Western studies. Future 
statistically robust prospective studies are strongly war-
ranted to further investigate the role of  CRT in the field 
of  D2-dissection. 
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Figure 2  Schematic diagram of lymph node station. LN: Lymph node; 7: 
LN along the left gastric artery; 8: LN along the common hepatic artery; 9: LN 
around the celiac artery; 10: LN at the splenic hilum; 11: LN along the proximal 
splenic artery; 12: LN in the hepatoduodenal ligament; 13: LN on the posterior 
surface of the pancreatic head; 14: LN along the superior mesenteric vessels; 
16a: LN from the upper margin of the celiac trunk to the lower margin of the 
left renal vein; 16b: LN from the upper margin of the left renal vein to the aortic 
bifurcation.
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